Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: The effect the effects of the treatment for 28 days with fluoxetine (10 mg/kg), or escitalopram (2 mg/kg) on memory performance of C57Bl/6J mice in MBM. (A) Presents a schematic diagram of injections and experimental schedule. (B) Acquisition experiments–latency to find an escape hole. (C) Acquisition experiments–the number of errors; latency to find escape box. (D) Latency to find an escape hole. (E) The number of errors. (F) Representative tracking images. (G) Proportion of strategy use. Values are expressed as the means ± S.E.M., and were evaluated by one-way (B,C) and repeated measure ANOVA (D,E) , and histogram of frequency distribution (G) , (n = 8). Asterisk on represents Post Hoc Newman-Keuls test.

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: The effects of the treatment for 28 days with fluoxetine (10 mg/kg), or escitalopram (2 mg/kg) on selected memory parameters in MBM. (A) Schematic diagram of injections and experimental schedule using MBM. (B) The effects of the treatment for 28 days with fluoxetine (10 mg/kg), or escitalopram (2 mg/kg) on wiping memory traces in MBM. (C) The effects of the treatment for 28 days with fluoxetine (10 mg/kg), or Escitalopram (2 mg/kg) on working memory in MBM. (D) The effects of the treatment for 28 days with fluoxetine (10 mg/kg), or escitalopram (2 mg/kg) on memory flexibility in MBM. One-way ANOVA, followed by Dunnet, n = 8. Values are expressed as the means ± S.E.M., *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle group. Asterisk on represents Post Hoc Newman-Keuls test.

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques:

Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: (a) FRIR spectra ±SD of amygdala collected from control group (black color), fluoxetine group (red color) and escitalopram group (green color); PCA analysis (b1) with loading plots (b2) for FTIR lipids region (2,800–3,000 cm -1 ).

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: (a) FRIR spectra ±SD of prefrontal cortex collected from control group (black color), fluoxetine group (red color) and escitalopram group (green color); PCA analysis (b1) with loading plots (b2) for FTIR lipids region (2,800–3,000 cm -1 ).

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: (a) FRIR spectra ±SD of hippocampus collected from control group (black color), fluoxetine group (red color) and escitalopram group (green color); PCA analysis (b1) with loading plots (b2) for FTIR lipids region (2,800–3,000 cm-1).

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques: Control

Journal: Frontiers in Pharmacology

Article Title: Impact of chronic SSRI administration on memory parameters, lipid components and membrane properties in C57Bl/6J mice

doi: 10.3389/fphar.2026.1769754

Figure Lengend Snippet: Elastic modulus of murine prefrontal cortex (pFCx–red histogram) and hippocampus (HP–green histogram): (A,B) bare tissue, (C,D) fluoxetine treatment and (E,F) escitalopram treatment. Chronic treatment.

Article Snippet: The following drugs were used: fluoxetine hydrochloride (Carbosynth limited, United Kingdom); escitalopram (H. Lundbeck A/S, Copenhagen).

Techniques:

Journal: ACS Omega

Article Title: Complexation of Citalopram with β‑Cyclodextrin, Mono-subetadex, and Subetadex: Phase Solubility, Hummel–Dreyer, Affinity Capillary Electrophoresis, ITC, and NMR Studies

doi: 10.1021/acsomega.5c13544

Figure Lengend Snippet: Schematic structure of the studied CDs and the chemical structure of citalopram.

Article Snippet: Citalopram (racemic) and S-citalopram oxalate were purchased from TCI (Tokyo, Japan).

Techniques:

Journal: ACS Omega

Article Title: Anxiolytic-Like Effect of Hyptis crenata Essential Oil: Behavioral Insights and In Silico SERT Modulation

doi: 10.1021/acsomega.5c11201

Figure Lengend Snippet: Human serotonin transporter complexed with s-citalopram. Binding at the primary and secondary sites using PDB 5I75 as a guide for studying the serotonin reuptake transporter.

Article Snippet: The reference drugs mirtazapine and citalopram (Sanofi Medley, Campinas, São Paulo, Brazil) were also diluted in saline solution and administered at doses of 30 mg/kg and 10 mg/kg, respectively.

Techniques: Binding Assay

Journal: bioRxiv

Article Title: Sublethal stress from polypharmacy modulates scavenging function and fenestrations in mouse liver sinusoidal endothelial cells

doi: 10.64898/2026.02.23.707391

Figure Lengend Snippet: (A,B) LSEC viability after 5 h exposure to citalopram (3.54 and 11.80 ng/mL), oxybutynin (0.07 and 0.12 ng/mL), metoprolol (97.23 and 313.61 ng/mL), oxycodone (0.15 and 0.50 ng/mL), or the high DBI polypharmacy cocktail at steady-state (concentrations were approximately two-fold higher than those observed during monotherapy) (A) or first-pass (B) concentrations. (C,D) Scavenger receptor-mediated endocytosis of 125 I-FSA measured after exposure to the same drug concentrations at steady-state (C) or first-pass (D). Light bars indicate cell-associated ligand and dark bars indicate degraded ligand. Data are normalized to the untreated control (0.01% DMSO) and are expressed as mean ± standard deviation of 3-4 independent biological replicates. Statistical significance is indicated in the graphs ( p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***)

Article Snippet: LSEC were treated with either the steady-state concentration or the first-pass concentration of citalopram (Merck), oxybutynin (Merck), metoprolol (Merck) and oxycodone (Lipomed), both as monotherapies and a high-DBI cocktail containing all four drugs.

Techniques: Control, Standard Deviation

Journal: bioRxiv

Article Title: Sublethal stress from polypharmacy modulates scavenging function and fenestrations in mouse liver sinusoidal endothelial cells

doi: 10.64898/2026.02.23.707391

Figure Lengend Snippet: (A) Representative scanning electron microscopy images of LSEC after 5 h treatment with citalopram (3.54 and 11.80 ng/mL), oxybutynin (0.07 and 0.12 ng/mL), metoprolol (97.23 and 313.61 ng/mL), oxycodone (0.15 and 0.50 ng/mL), or the high DBI polypharmacy cocktail at steady-state (concentrations were approximately two-fold higher than those observed during monotherapy). Scalebar = 5 µm and inset diameter = 4 µm. (B,C) Quantitative analysis of fenestrated morphology: porosity (percentage of cell surface covered by fenestrations, B) and fenestration frequency (number of fenestrations per µm 2 , C). Each dot represents a single cell (45–60 per treatment), and black lines indicate mean values from 3–4 independent biological replicates. Data is normalized to the untreated control (0.01% DMSO). Statistical significance was assessed using Kruskal-Wallis test with Dunn’s multiple comparisons; significance levels are denoted using the conventional asterisks annotation: p ≥ 0.05 = ns, p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***.

Article Snippet: LSEC were treated with either the steady-state concentration or the first-pass concentration of citalopram (Merck), oxybutynin (Merck), metoprolol (Merck) and oxycodone (Lipomed), both as monotherapies and a high-DBI cocktail containing all four drugs.

Techniques: Electron Microscopy, Single Cell, Control

Journal: bioRxiv

Article Title: Sublethal stress from polypharmacy modulates scavenging function and fenestrations in mouse liver sinusoidal endothelial cells

doi: 10.64898/2026.02.23.707391

Figure Lengend Snippet: (A) Representative scanning electron microscopy images of LSEC after 5 h treatment with citalopram (3.54 and 11.80 ng/mL), oxybutynin (0.07 and 0.12 ng/mL), metoprolol (97.23 and 313.61 ng/mL), oxycodone (0.15 and 0.50 ng/mL), or the high DBI polypharmacy cocktail at steady-state (concentrations were approximately two-fold higher than those observed during monotherapy). Scalebar = 5 µm and inset diameter = 4 µm. (B,C) Quantitative analysis of fenestrated morphology: porosity (percentage of cell surface covered by fenestrations, B) and fenestration frequency (number of fenestrations per µm 2 , C). Each dot represents a single cell (45–60 per treatment), and black lines indicate mean values from 3–4 independent biological replicates. Data is normalized to the untreated control (0.01% DMSO). Statistical significance was assessed using Kruskal-Wallis test with Dunn’s multiple comparisons; significance levels are denoted using the conventional asterisks annotation: p ≥ 0.05 = ns, p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***.

Article Snippet: LSEC were treated with either the steady-state concentration or the first-pass concentration of citalopram (Merck), oxybutynin (Merck), metoprolol (Merck) and oxycodone (Lipomed), both as monotherapies and a high-DBI cocktail containing all four drugs.

Techniques: Electron Microscopy, Single Cell, Control